

10/224  
D12/3434



Rebecca Doolan  
Project Manager  
Labelling and Packaging Review  
Therapeutic Goods Administration

email: [labellingreview@tga.gov.au](mailto:labellingreview@tga.gov.au)

AUSTRALIAN MEDICAL  
ASSOCIATION  
ABN 37 008 426 793

T | 61 2 6270 5400  
F | 61 2 6270 5499  
E | [info@ama.com.au](mailto:info@ama.com.au)  
W | [www.ama.com.au](http://www.ama.com.au)

42 Macquarie St Barton ACT 2600  
PO Box 6090 Kingston ACT 2604

Dear Ms Doolan

### **TGA labelling and packaging of medicines review consultation**

Thank you for the opportunity to provide feedback on the TGA's Medicine Labelling and Packaging Review consultation paper.

The AMA commends the work of the TGA to improve consumer safety and reduce the risks. We support the recommendations made in the consultation paper; they appear consistent and sensible.

Additional measures to further strengthen the recommendations are:

- the active ingredient should be placed above the brand name and appear more prominent in size, font and colour;
- the warning 'contains gluten' should be included within the medicine information box; and
- there should be minimum standards for the legibility of expiry dates, to ensure they are not too small or transparent to be easily read.

If you have any queries, please contact Ms Georgia Morris on (02) 6270 5466 or [gmmorris@ama.com.au](mailto:gmmorris@ama.com.au) in the first instance.

Yours sincerely

A handwritten signature in black ink, appearing to read 'Geoff Dobb', with a horizontal line extending from the end of the signature.

Professor Geoff Dobb  
AMA Vice President  
Chair, AMA Therapeutics Committee

6 August 2012

gd:gm